Neuron Specific Enolase in Ventricular Assist Device Recipients (NSE-LVAD)

University of Minnesota (UMN)

Status: Completed

Conditions: Left Ventrucular Assist Device; Advanced Heart Failure

Study type: Observational

Funder types: Other

Identifiers

NCT01643551

1204M12861

Details and patient eligibility

About

An observational study of neuron specific enolase, as a marker of reperfusion injury, in LVAD recipients before and following VAD implantation.

Full description

Patients eligible for left ventricular assist device (LVAD) typically have severe heart failure, which is characterized by poor cardiac output. The relatively abrupt increase in cardiac output that follows implant of a LVAD may cause reperfusion injury. Furthermore, selected patients may have particularly severe consequences of such injury, including refractory acidosis and vasoplegia. Neuron specific enolase (NSE) has been established as a biomarker of reperfusion injury. We hypothesize that changes in NSE following LVAD will be greater than the changes in NSE noted in a control population of patients undergoing non-VAD cardiac surgery.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Group 1 - Pre-VAD implantation patients

• 18 years and older
• lanning to undergo VAD implantation Group 2 Cardiac Surgery Comparison Group
• 18 years or older
• Planning to undergo valve or coronary bypass surgery

Exclusion criteria

• Acute cerebrovascular infarction

Trial design

15 participants in 2 patient groups

LVAD Group

Description:

18 years and older Planning to undergo VAD implantation

Cardiac Surgery Group

Description:

18 years or older Planning to undergo valve or coronary bypass surgery